Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. progressive liver disease
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Progressive Liver Disease Articles & Analysis: Older

209 news found

Tethis S.p.A. Collaborates with Weill Cornell Medicine to Advance Cellular Residual Disease Monitoring in Early-Stage Breast Cancer

Tethis S.p.A. Collaborates with Weill Cornell Medicine to Advance Cellular Residual Disease Monitoring in Early-Stage Breast Cancer

Milan, Italy, September 3, 2024 — Tethis S.p.A., a pioneer in the development of a standardized liquid biopsy platform, announces a collaboration with Weill Cornell Medicine to test Tethis’ instruments for monitoring the response to curative treatment in patients with early-stage breast cancer. The scientists will collect blood from the patients and will measure the number and kind ...

ByTethis S.p.A


Dual Benefits of Compound 17B For Pulmonary Arterial Hypertension

Dual Benefits of Compound 17B For Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition characterized by increased pulmonary arterial pressure, vascular remodeling, and persistent inflammation. Despite advances in treatment, current therapies—such as sildenafil, iloprost, and riociguat—primarily focus on reducing symptoms by dilating blood vessels. Unfortunately, these therapies do ...

BySCIREQ - an emka TECHNOLOGIES Company


Ace Therapeutics Releases Cardiovascular Disease Model Development Services to Power Up Related Preclinical Research

Ace Therapeutics Releases Cardiovascular Disease Model Development Services to Power Up Related Preclinical Research

Ace Therapeutics is proud to announce the launch of its cardiovascular disease model development services, aiming to empower researchers and pharmaceutical companies with advanced tools and models to accelerate the study of cardiovascular diseases and drug discovery. Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, underscoring the urgent need for ...

ByAce Therapeutics


Influenza A Virus Mouse Models for Accelerated Research

Influenza A Virus Mouse Models for Accelerated Research

As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its innovative Influenza A Virus Mouse Models to assess the impact of virus-host interactions. These mouse models can facilitate comprehensive research into the pathogenesis, immune response, and efficacy of antiviral treatments against influenza A infections. ...

ByCreative Diagnostics


Validating The BLEO-Induced Mouse Model For Drug Discovery

Validating The BLEO-Induced Mouse Model For Drug Discovery

Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by progressive scarring of the lungs, which severely impairs lung function over time. Developing effective treatments for IPF has been a challenge for the medical community, as the mechanisms driving this disease are complex and not fully understood. To accelerate drug discovery, animal models that closely mimic the ...

BySCIREQ - an emka TECHNOLOGIES Company


Advanced Lung Function Measurement In A Novel HIV/Tuberculosis Co-Infection Mouse Model

Advanced Lung Function Measurement In A Novel HIV/Tuberculosis Co-Infection Mouse Model

Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) are major global health threats. Their interaction worsens disease severity, as HIV reduces CD4+ T cells, making individuals more vulnerable to TB. Despite progress, an effective animal model that mimics human immune response during HIV/TB co-infection has been lacking, hindering treatment and vaccine development. Bohorguez et al. ...

BySCIREQ - an emka TECHNOLOGIES Company


CD Genomics Launches Advanced Whole Exome Sequencing Service, Empowering Genetic Research

CD Genomics Launches Advanced Whole Exome Sequencing Service, Empowering Genetic Research

CD Genomics, a renowned provider of genomics services, is proud to unveil its cutting-edge Whole Exome Sequencing (WES) service. This offering provides researchers and clinicians with a powerful tool to investigate the exome, shedding light on the intricacies of the human genome and propelling our understanding of genetic diseases. In the era of precision medicine, comprehensive and precise ...

ByCD Genomics


Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years

Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years

Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to Eylea (aflibercept 2 mg) at fixed 8-weekly dosing over two years Patients assigned to a 16-week dosing regimen at baseline received a mean of 7.8 injections (6 fewer than Eylea) Safety profile of aflibercept 8 mg in diabetic macular edema (DME) remains comparable to Eylea ...

ByBayer AG


Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) CKD affects up to 40% of people with T1D A quarter of people with CKD associated with T1D progress to end-stage kidney disease Only limited treatment options are available for people with CKD and ...

ByBayer AG


New data from pivotal studies with aflibercept 8 mg

New data from pivotal studies with aflibercept 8 mg

New Subgroup and further analyses from PULSAR, PHOTON and CANDELA provide insights into durability results of extended treatment intervals, patient characteristics as well as efficacy and safety of intravitreal aflibercept 8 mg In total, 18 presentations on aflibercept 8 mg and Eylea (aflibercept 2 mg) reinforce Bayer’s commitment to advancing treatment of patients with exudative retinal ...

ByBayer AG


Nubeqa (darolutamide) approved for additional prostate cancer indication in China

Nubeqa (darolutamide) approved for additional prostate cancer indication in China

Nubeqa now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additional indication based on data from the pivotal Phase III ARASENS trial The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) in combination with docetaxel for the ...

ByBayer AG


The Importance of Optimal Medical Therapy (OMT) and Collaborative Care

The Importance of Optimal Medical Therapy (OMT) and Collaborative Care

The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...

ByHeart Failure Society of America, Inc. (HFSA)


Ionis Announces Fda Acceptance Of New Drug Application For Eplontersen For The Treatment Of Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)

Ionis Announces Fda Acceptance Of New Drug Application For Eplontersen For The Treatment Of Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)

CARLSBAD, Calif., March 7, 2023 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The application has been given ...

ByHeart Failure Society of America, Inc. (HFSA)


New real world study data on reduced risk of adverse kidney outcomes for Xarelto compared to VKA

New real world study data on reduced risk of adverse kidney outcomes for Xarelto compared to VKA

In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD), compared to vitamin K antagonists (VKA) XARENO evaluated the impact of Xarelto in patients with NVAF and CKD, given that ...

ByBayer AG


Heart Failure Awareness 365: Nutrition/Diet/Exercise

Heart Failure Awareness 365: Nutrition/Diet/Exercise

March 2023's Heart Failure Awareness 365 campaign is focusing on: Nutrition/Diet/Exercise. While these three things are important for any individual's everyday health, they can have an even bigger impact if you're living with heart failure. Not only can properly managing these parts of your health alleviate heart failure symptoms, but they can also slow the disease's progression. ...

ByHeart Failure Society of America, Inc. (HFSA)


Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer

Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer

European Commission granted approval of Nubeqa (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) Approval is based on Phase III ARASENS trial data The European Commission has granted marketing authorization in the European Union (EU) for Nubeqa™ (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation ...

ByBayer AG


Bayer submits aflibercept 8 mg for marketing authorization in Japan

Bayer submits aflibercept 8 mg for marketing authorization in Japan

Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PULSAR and PHOTON In both trials, aflibercept 8 mg demonstrated unprecedented durability results with treatment intervals of up to 16 weeks, with ...

ByBayer AG


Nubeqa approved for additional indication in Japan

Nubeqa approved for additional indication in Japan

Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer New approval based on data from the pivotal Phase III ARASENS trial The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the indication of metastatic prostate ...

ByBayer AG


Why Knowledge Is Power In The Treatment Of Obesity

Why Knowledge Is Power In The Treatment Of Obesity

Dr. Ali Tinazli is the CEO of lifespin.health and has 15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP). Obesity rates continue to climb alongside a $254.9 billion global weight loss products and services market. Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 ...

ByLifespin GmbH


New data presented at ASCO GU confirm survival benefits and favorable safety profile of darolutamide across different subgroups of patients with metastatic hormone-sensitive prostate cancer

New data presented at ASCO GU confirm survival benefits and favorable safety profile of darolutamide across different subgroups of patients with metastatic hormone-sensitive prostate cancer

New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS) and improved key clinically relevant endpoints in patients with various types of metastatic disease burden and risk, compared to ADT with docetaxel alone Favorable safety profile of darolutamide plus ADT in combination ...

ByBayer AG

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT